ИнТОР - Репозиторијум Институтa „Торлак“
Институт за вирусологију, вакцине и серуме „Торлак“
    • English
    • Српски
    • Српски (Serbia)
  • Српски (ћирилица) 
    • Енглески
    • Српски (ћирилица)
    • Српски (латиница)
  • Пријава
Преглед записа 
  •   ИнТОР
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
  •   ИнТОР
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
JavaScript is disabled for your browser. Some features of this site may not work without it.

Allergenicity and immunogenicity of the major mugwort pollen allergen Art v 1 chemically modified by acetylation

Само за регистроване кориснике
2009
Аутори
Perović, I.
Milovanović, Mina
Stanić, Dragana
Burazer, Lidija
Petrović, D.
Milčić-Matić, Natalija
Gafvelink, G.
van Hage, Marianne
Jankov, Ratko
Ćirković-Veličković, Tanja
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документу
Апстракт
Treating allergies with modified allergens is an approach to make the treatment safer and more efficient. Art v 1 is the most prominent allergen of mugwort pollen and a significant cause of hayfever around Europe. The aim of this study was to reduce the allergenicity of Art v 1 by acetylation, and to investigate the capacity of the modified protein to generate blocking antibodies. The reduction of allergenicity of Art v 1 following acetylation was monitored by immunoblot, ELISA inhibition using a pool of sera from mugwort pollen allergic patients, basophil activation assay and by skin prick testing of mugwort-allergic patients. Rabbits were immunized against Art v 1 and acetylated Art v 1 (acArt v 1) and the rabbit antisera were tested for their capacity to block human IgE binding in ELISA. Human T cell proliferation against Art v 1 and acArt v 1 was examined in peripheral blood mononuclear cells (PBMCs) of mugwort pollen allergic patients and cytokine release in PBMC cultures was moni...tored. Acetylation of Art v 1 gave a derivative of reduced allergenicity in the in vitro and ex vivo tests applied. The skin test reactivity to acArt v 1 was significantly reduced in 19 patients when compared with the reactivity to Art v 1. Rabbit antibodies to acArt v 1 and Art v 1 showed similar capacity to block human IgE binding to Art v 1 in inhibition ELISA. Both proteins were able to induce proliferation of PBMCs and CD3/CD4(+) cells of mugwort-allergic patients. Release of IL-5 was significantly reduced in cultures stimulated with acArt v 1. Art v 1 modified by acetylation had a significantly reduced allergenicity in vitro and in vivo, while its immunogenicity was retained. Modification of allergens by acetylation could be a new strategy for allergen-specific immunotherapy. Cite this as: I. Perovic, M. Milovanovic, D. Stanic, L. Burazer, D. Petrovic, N. Milcic-Matic, G. Gafvelin, M. van Hage, R. Jankov and T. Cirkovic Velickovic, Clinical and Experimental Allergy, 2009 (39) 435-446.

Кључне речи:
acetylation / allergen-specific immunotherapy / allergoid / Art v 1 / blocking antibodies / mugwort pollen allergy
Извор:
Clinical and Experimental Allergy, 2009, 39, 3, 435-446
Издавач:
  • Wiley, Hoboken
Финансирање / пројекти:
  • Испитивање структуре и функције биолошки важних макромолекула у физиолошким и патолошким стањима (RS-142020)

DOI: 10.1111/j.1365-2222.2008.03158.x

ISSN: 0954-7894

PubMed: 19178539

WoS: 000262879100018

Scopus: 2-s2.0-58849114494
[ Google Scholar ]
URI
http://intor.torlakinstitut.com/handle/123456789/270
Колекције
  • Radovi istraživača / Researchers’ publications
Институција/група
Torlak

DSpace software copyright © 2002-2015  DuraSpace
О репозиторијуму ИнТОР | Пошаљите запажања

OpenAIRERCUB
 

 

Комплетан репозиторијумГрупеАуториНасловиТемеОва институцијаАуториНасловиТеме

Статистика

Преглед статистика

DSpace software copyright © 2002-2015  DuraSpace
О репозиторијуму ИнТОР | Пошаљите запажања

OpenAIRERCUB